233 related articles for article (PubMed ID: 23226015)
1. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.
Vijayasaratha K; Stockley RA
Int J Chron Obstruct Pulmon Dis; 2012; 7():789-96. PubMed ID: 23226015
[TBL] [Abstract][Full Text] [Related]
2. Patterns and characterization of COPD exacerbations using real-time data collection.
Ejiofor SI; Stolk J; Fernandez P; Stockley RA
Int J Chron Obstruct Pulmon Dis; 2017; 12():427-434. PubMed ID: 28182151
[TBL] [Abstract][Full Text] [Related]
3. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
4. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
5. A score to predict short-term risk of COPD exacerbations (SCOPEX).
Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.
Omachi TA; Eisner MD; Rames A; Markovtsova L; Blanc PD
Respir Res; 2011 Mar; 12(1):35. PubMed ID: 21429222
[TBL] [Abstract][Full Text] [Related]
7. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
8. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
9. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.
Calverley PM; Anzueto AR; Dusser D; Mueller A; Metzdorf N; Wise RA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1297-1308. PubMed ID: 29719385
[TBL] [Abstract][Full Text] [Related]
10. Correlation between annual change in health status and computer tomography derived lung density in subjects with alpha1-antitrypsin deficiency.
Stolk J; Ng WH; Bakker ME; Reiber JH; Rabe KF; Putter H; Stoel BC
Thorax; 2003 Dec; 58(12):1027-30. PubMed ID: 14645966
[TBL] [Abstract][Full Text] [Related]
11. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
12. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
13. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline.
Dowson LJ; Guest PJ; Stockley RA
Am J Respir Crit Care Med; 2001 Nov; 164(10 Pt 1):1805-9. PubMed ID: 11734427
[TBL] [Abstract][Full Text] [Related]
14. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2007 Sep; 132(3):909-15. PubMed ID: 17573491
[TBL] [Abstract][Full Text] [Related]
15. Emphysematous phenotype is an independent predictor for frequent exacerbation of COPD.
Oh YM; Sheen SS; Park JH; Jin UR; Yoo JW; Seo JB; Yoo KH; Lee JH; Kim TH; Lim SY; Yoon HI; Lee JS; Lee SD
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1407-14. PubMed ID: 25517804
[TBL] [Abstract][Full Text] [Related]
16. Exacerbation frequency and course of COPD.
Halpin DM; Decramer M; Celli B; Kesten S; Liu D; Tashkin DP
Int J Chron Obstruct Pulmon Dis; 2012; 7():653-61. PubMed ID: 23055714
[TBL] [Abstract][Full Text] [Related]
17. Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?
Kim J; Kim WJ; Lee CH; Lee SH; Lee MG; Shin KC; Yoo KH; Lee JH; Lim SY; Na JO; Hwang HG; Hong Y; Lim MN; Yoo CG; Jung KS; Lee SD
Respir Res; 2017 May; 18(1):107. PubMed ID: 28558829
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
Rahaghi FF; Miravitlles M
Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
[TBL] [Abstract][Full Text] [Related]
19. Expiratory flow limitation relates to symptoms during COPD exacerbations requiring hospital admission.
Jetmalani K; Timmins S; Brown NJ; Diba C; Berend N; Salome CM; Wen FQ; Chen P; King GG; Farah CS
Int J Chron Obstruct Pulmon Dis; 2015; 10():939-45. PubMed ID: 25999709
[TBL] [Abstract][Full Text] [Related]
20. Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.
Coutinho AD; Lokhandwala T; Boggs RL; Dalal AA; Landsman-Blumberg PB; Priest J; Stempel DA
Int J Chron Obstruct Pulmon Dis; 2016; 11():1223-31. PubMed ID: 27354781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
